Moreover, Nomizo et al. [31] indicated that the CC and CG genotypes and C-allele of PD-L1 rs4143815 were significantly associated with a better objective response rate and progression-free survival in NSCLC patients treated with nivolumab, and therefore, they suggested that the PD-L1 rs4143815 may be a biomarker for identifying patients for whom nivolumab might be particularly beneficial. This evidence concerns the gene CD274 and non-small cell lung carcinoma.